DC
BHVN

Diametric Capital’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Diametric Capital’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,197
Closed -$320K – 400
2022
Q2 		$320K Buy
+2,197
New +$281K 0.24% 151
2020
Q3 		– Sell
-3,352
Closed -$245K – 234
2020
Q2 		$245K Buy
+3,352
New +$178K 0.19% 112
2020
Q1 		– Sell
-6,043
Closed -$329K – 186
2019
Q4 		$329K Buy
+6,043
New +$299K 0.24% 97

Other funds holding BHVN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SFM
Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Diametric Capital's BHVN Position: Q3 2022 in Review

Diametric Capital sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2022, closing a stake of 2,197 shares — an estimated $320K sold.

Diametric Capital first reported a position in BHVN in Q4 2019 and held it in 3 quarters. The position peaked at $329K in Q4 2019. 240 funds tracked by Wall St. Rank hold BHVN as of Q3 2022.

  • Diametric Capital reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2022 after selling out during the quarter.
  • Diametric Capital sold 2,197 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2022, an estimated $320K.
  • Diametric Capital first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2019 and held it in 3 quarters.
  • Diametric Capital's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $329K in Q4 2019.
  • 240 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2022.

Based on Diametric Capital's 13F filing for Q3 2022, filed 14 Nov 2022.